2010 Annual Scientific Meeting and Exposition 2010 Annual ...

More documents

Recommendations

Info

MAY 2PostersSunday MorningPregnancyPO-214: 1PO-215: 1PO-216: 2Women with Previous Preeclampsia are at IncreasedRisk for Developping Hypertension After CombinedOral ContraceptivesJorge Polonia, 1 Filomena Cardoso, 3 Jose A. Silva, 1Helena Belchior, 2 Pedro Tiago, 2 Joao Silva-Carvalho. 31 Blood Pressure Unit, Matosinhos, PT; 2 Obstetricia& Ginecologia, Matosinhos, PT and 3 Obstetriia &Ginecologia, Porto, PT.Low Potassium and Uric Acid Level During the FirstHalf of Pregnancy is Associated with Lower Risk forthe Development of Gestational Diabetes Mellitusand PreeclampsiaTalya Wolak, 1 Esther Paran, 1 Ruslan Sergienco, 3Arnon Wiznitzer, 2 Lior Ben-Shlush, 2 Eyal Sheiner. 21 Hypertension Unit, Soroka University Hospital, Beer-Sheba, IL; 2 Department of Obstetrics and GynecologySoroka University Hospital, Beer-Sheba, IL and3 Epidemiology and Health Services Evaluation Facultyof Health Sciences, Ben Gurion University of theNegev, Beer-Sheba, IL.Evaluation of Left Ventricular Structure andFunction and Carotid Artery Morphology in Womenwith Previous PreeclampsiaMassimo Salvetti, 1 Federico Perfumo, 2 Anna Paini, 1Giorgia Gatti, 2 Claudia Agabiti Rosei, 1 Carlo Aggiusti, 1Enrico Agabiti Rosei, 1 Tiziana Frusca, 2 Maria LorenzaMuiesan. 1 1 Internal Medicine, University of Brescia,IT and 2 Obstetrics and Gynaecology, University ofBrescia, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track140
Monday Morning Afternoon MAY 21 3PostersPosters will be displayed in the Rhinelander Gallery.Monday, May 3, 2010Posters on Display: 9:00 AM – 5:15 PM • Poster Viewing: 4:15 PM – 5:15 PMCellular Mechanisms (Cell Biology;Cell Membrane Transport/Ion Channels;Coagulation/Thrombosis; Growth Factors).............(PO-217 – PO-219)Clinical Trials................................................................(PO-220 – PO-242)Endothelial Function...................................................(PO-243 – PO-255)Epidemiology/Special Populations............................(PO-256 – PO-293)Genetics/Gene Therapy/Proteomics..........................(PO-294 – PO-297)Neural Hormonal Mechanisms (Renin;Neural Control; Vasoactive Autacoids).....................(PO-298 – PO-300)Obesity...........................................................................(PO-301 – PO-306)Pediatric Hypertension...............................................(PO-307 – PO-308)Preclinical Models/ExperimentalHypertension................................................................(PO-309 – PO-311)Vascular Injury/Inflammation andRemodeling...................................................................(PO-312 – PO-318)Late-Breaking Posters........................................(LBPO-001 – LBPO-016)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.1 Pathobiology Track 2 Translational Track 3 Therapy Track141
Page 1 and 2:
American Society of Hypertension201
Page 3 and 4:
Valturna offers bothsuperior BP eff
Page 5 and 6:
Figure 2: Probability of Achieving
Page 7 and 8:
potential for other drugs acting on
Page 9 and 10:
aliskiren arms were about one-third
Page 11 and 12:
As with other drugs that block angi
Page 13:
American Society of Hypertension201
Page 18:
Program Color KeyThe pages of this
Page 21 and 22:
General InformationThis program boo
Page 23 and 24:
General Information continuedHilton
Page 25 and 26:
General Information continuedASH Sc
Page 27 and 28:
General Information continuedASH Hy
Page 29 and 30:
2010 ASH Corporate MembersBoehringe
Page 31 and 32:
ASH Leadership2009-2010 Board of Di
Page 33 and 34:
Special LectureMonday, May 3, 2010,
Page 35 and 36:
Special LectureMonday, May 3, 2010,
Page 37 and 38:
2010 Abstract Reviewers continuedEr
Page 39 and 40:
Visit TEKTURNA at Booth 1100.and/or
Page 41 and 42:
5.5 HyperkalemiaIncreases in serum
Page 43 and 44:
with Pgp substrates or weak to mode
Page 45 and 46:
ASH Program at a GlanceSaturday, Ma
Page 47 and 48:
ASH Program at a GlanceMonday, May
Page 49 and 50:
Poster Category PresentationPosters
Page 51 and 52:
2010 ASH Faculty continuedJeffrey R
Page 53 and 54:
2010 ASH Faculty continuedAndrew Wh
Page 55 and 56:
2010American Societyof Hypertension
Page 57 and 58:
Saturday Afternoon MAY 1PostersPost
Page 59 and 60:
Saturday Afternoon MAY 1Sessions3:3
Page 61 and 62:
Saturday Afternoon MAY 1Sessions3:3
Page 63 and 64:
Sunday Morning MAY 2Satellite Sympo
Page 65 and 66:
Sunday Morning MAY 2Sessions contin
Page 67 and 68:
Sunday Morning MAY 2Sessions8:00 AM
Page 69 and 70:
Sunday Morning MAY 2Sessions10:00 A
Page 71 and 72:
Sunday Morning MAY 2Sessions10:00 A
Page 73 and 74:
Sunday Afternoon MAY 2Sessions3:30
Page 75 and 76:
Sunday Afternoon MAY 2Sessions3:30
Page 77 and 78:
Sunday Afternoon MAY 2Special Sessi
Page 79 and 80:
Sunday Evening MAY 2Sessions6:00 PM
Page 81 and 82:
Sunday Evening MAY 2Sessions6:00 PM
Page 83 and 84:
Monday Morning MAY 3Satellite Sympo
Page 85 and 86:
Monday Morning MAY 3Sessions8:00 AM
Page 87 and 88:
Monday Morning Afternoon MAY 21 3Po
Page 89 and 90:
Monday Morning MAY 3Sessions10:00 A
Page 91 and 92: Monday Morning MAY 3Sessions10:00 A
Page 93 and 94: Monday Morning MAY 3Sessions11:45 A
Page 95 and 96: Monday Evening May 3Satellite Sympo
Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
Page 101 and 102: Tuesday Morning MAY 4ASH Membership
Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
Page 105 and 106: 2010American Societyof Hypertension
Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
Page 125 and 126: Sunday Morning MAY 2PostersPosters
Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
Page 129 and 130: Sunday Morning MAY 2PostersPO-123:
Page 141: Sunday Morning MAY 2PostersPO-206:
Page 145 and 146: Monday Morning Afternoon MAY 21 3Po
Page 161 and 162: Monday Morning Afternoon May 213Pos
Page 163 and 164: Faculty Disclosure ListingGail Adle
Page 165 and 166: Faculty Disclosure Listing continue
Page 173 and 174: you to attend thethe Innovations Th
Page 175 and 176: 5.5 HyperkalemiaIncreases in serum
Page 177 and 178: with Pgp substrates or weak to mode
Page 179 and 180: Valturna (aliskiren and valsartan,
Page 181 and 182: 4 CONTRAINDICATIONSNone.5 WARNINGS
Page 183 and 184: een reported. In a 4-day trial of v
Page 185 and 186: 7 DRUG INTERACTIONSNo drug interact
Page 187 and 188: 8.5 Geriatric UseIn 8.5the Geriatri
Page 189 and 190: 2010 ASH ExhibitorsASH Hypertension
Page 191 and 192: ASH Hypertension Resource CenterHil
Page 193 and 194:
2010 ASH Exhibitors continuedCVRx I
Page 195 and 196:
2010 ASH Exhibitors continuedIntern
Page 197 and 198:
2010 ASH Exhibitors continuedNature
Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
Page 203 and 204:
Author IndexCastellano, Maurizio, 1
Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
Page 207 and 208:
Author IndexLekakis, John, 118, 122
Page 209 and 210:
Author IndexPittaras, Andreas, 149P
Page 211 and 212:
Author IndexTello, Susana, 109, 135
Page 213 and 214:
Hilton New York Floor PlansSecond F
Page 215 and 216:
Hilton New York Floor PlansFourth F
Page 218:
Are You 1in 3?Get the facts. Know y
show all

2010 Annual Scientific Meeting and Exposition 2010 Annual ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?